- Ibrutinib, sold
under the
brand name
Imbruvica among others, is a
small molecule drug that
inhibits B-cell
proliferation and
survival by irreversibly...
- Its
other major products include Botox ($5.7 billion in 2023 revenues),
Imbruvica to
treat cancer ($3.6 billion in 2023 revenues),
Rinvoq to
treat arthritis...
-
Imbruvica), a B cell
cancer drug
highly effective for
treating chronic lymphocytic leukemia (CLL), the most
common form of
adult leukemia.
Imbruvica was...
-
Xeplion Oncology therapies Balversa Carvykti Dacogen Darzalex Eprex Erleada Imbruvica Procrit Rybrevant Talvey Tecvayli Valchlor Velcade Yondelis Zytiga Cardiovascular...
-
superior PFS
results from the
Phase 3
ALPINE head-to-head
trial versus Imbruvica in relapsed/refractory CLL.
BeiGene was
founded in late 2010 by John V...
-
kinase inhibitors (BTKi), one In
November 2013,
ibrutinib (brand name
Imbruvica,
Pharmacyclics LLC) and one in
October 2017,
acalabrutinib (brand name...
-
Balversa Concerta Darzalex Ditropan Duragesic Edurant Elmiron Erleada Haldol Imbruvica Intelence Invega Invokamet Invokana Prezcobix Prezista Procrit Razadyne...
-
acquire Pharmacyclics, as well as its lead anti-cancer
compound ibrutinib (
Imbruvica) for $21 billion. As part of the deal,
AbbVie will pay $261.25 per share...
- Bristol-Myers
Squibb to
manufacture two
biologic drugs.
Lonza also
manufactures Imbruvica for
Pharmacyclics and
Mydicar for Celladon. In 2015,
Lonza contracted...
- PMID 25853747. Goodin, Tara (29
January 2015). "FDA
expands approved use of
Imbruvica for rare form of non-Hodgkin lymphoma". FDA.
Retrieved 29
January 2015...
